MAPT and Alzheimer disease: Furthermore, we substantiate that the densely aligned CNT sensor array can discriminate clinically diagnosed AD patients from normal controls by estimating the levels of composite AD biomarkers (t-tau/Aβ42, p-tau/Aβ42, and Aβ42/Aβ40) in human plasma.